How long does a Wegovy approval last with Delaware Medicaid?

Liver Disease (MASH) — Applies to Medicaid plans. Initial approval: 6 months. Renewal: every 6 months.

What does Delaware Medicaid require to renew Wegovy?

Liver Disease (MASH) — Applies to Medicaid plans. Prescriber must attest that the member continues to derive clinical benefit with the requested agent AND that the member requires ongoing therapy as part of the treatment plan. Resubmission of initial coverage documentation is NOT required at reauthorization.

How current is this information?

The oldest review date among the policies on this page is June 4, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Delaware Medicaid coverage for Wegovy (Liver Disease

Does Delaware Medicaid cover Wegovy for Liver Disease (MASH)?

Yes. Delaware Medicaid covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy document

Delaware Medicaid Medicaid prior authorization policy

Delaware Medicaid · PA policy · Medicaid

Effective April 20, 2026. Verified June 4, 2026.

View PDF Download Original insurer source

Medicaid: Covered with requirements. See the qualification pathways below.

Earliest policy review June 4, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)

Applies to Medicaid plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH with moderate to advanced fibrosis

All of:

Moderate to advanced liver fibrosis consistent with stages F2 to F3
Fibrosis confirmed by biopsy OR non-invasive tests (e.g., FibroScan or MRE + MRI-PDFF)
Agent prescribed by or in conjunction with a hepatologist or gastroenterologist

Documentation to bring

Member's relevant medical records and/or pharmacy profile
Appropriate baseline diagnostic and safety biopsy, laboratory, and/or noninvasive test results confirming F2-F3 fibrosis
Documentation that agent is prescribed by or in consultation with a hepatologist or gastroenterologist (name and NPI of consulting provider required)
Documentation of reduced calorie diet
Documentation of increased physical activity
Confirmation that member is NOT currently on another GLP-1 agonist
Confirmation that member has no contraindicated conditions/medications with requested GLP-1
Pharmacy claims history or pharmacy profile

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
Renewal: Prescriber must attest that the member continues to derive clinical benefit with the requested agent AND that the member requires ongoing therapy as part of the treatment plan. Resubmission of initial coverage documentation is NOT required at reauthorization.

Not covered when

Currently on another GLP-1 agonist
Has a contraindicated condition/disease with the requested GLP-1 agonist
Currently on a contraindicated medication with the requested GLP-1 agonist
BMI ≥ 27 kg/m2 is NOT required (obesity is a risk factor but not a requirement)

Policy note: MASH indication explicitly states BMI ≥ 27 kg/m2 is NOT a requirement. Fibrosis must be stages F2 to F3 (moderate to advanced). Non-invasive test examples include FibroScan or MRE + MRI-PDFF. Specialist (hepatologist or gastroenterologist) must prescribe or be consulted. Initial authorization up to 6 months in ≤ 30-day supplies; reauthorization 6 months in ≤ 90-day supplies.

Policy effective April 20, 2026 · verified June 4, 2026 · source: Delaware Medicaid Medicaid prior authorization policy · View policy document (PDF)

Open on its own page →

Questions people ask

Does Delaware Medicaid cover Wegovy?: Yes. Delaware Medicaid covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with Delaware Medicaid?: Liver Disease (MASH) — Applies to Medicaid plans. Initial approval: 6 months. Renewal: every 6 months.
What does Delaware Medicaid require to renew Wegovy?: Liver Disease (MASH) — Applies to Medicaid plans. Prescriber must attest that the member continues to derive clinical benefit with the requested agent AND that the member requires ongoing therapy as part of the treatment plan. Resubmission of initial coverage documentation is NOT required at reauthorization.
How current is this information?: The oldest review date among the policies on this page is June 4, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Summary of Delaware Medicaid's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.